About Exact Sciences Corporation
https://www.exactsciences.comExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
CEO
Kevin T. Conroy
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 215
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
TD Cowen
Buy
Craig-Hallum
Buy
B of A Securities
Buy
Baird
Outperform
Evercore ISI Group
Outperform
Scotiabank
Sector Outperform
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
FMR LLC
Shares:18.65M
Value:$1.91B
VANGUARD GROUP INC
Shares:17.81M
Value:$1.82B
CAPITAL WORLD INVESTORS
Shares:16.14M
Value:$1.65B
Summary
Showing Top 3 of 744
About Exact Sciences Corporation
https://www.exactsciences.comExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $850.74M ▲ | $609.47M ▲ | $-19.59M ▼ | -2.3% ▼ | $-0.1 ▼ | $47.91M ▼ |
| Q2-2025 | $811.09M ▲ | $564.6M ▼ | $-1.19M ▲ | -0.15% ▲ | $-0.01 ▲ | $53.13M ▲ |
| Q1-2025 | $706.78M ▼ | $596.56M ▼ | $-101.22M ▲ | -14.32% ▲ | $-0.54 ▲ | $-38.11M ▲ |
| Q4-2024 | $713.42M ▲ | $1.31B ▲ | $-864.59M ▼ | -121.19% ▼ | $-4.67 ▼ | $-814.57M ▼ |
| Q3-2024 | $708.65M | $530.89M | $-38.24M | -5.4% | $-0.21 | $25.62M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1B ▲ | $5.9B ▲ | $3.4B ▲ | $2.5B ▲ |
| Q2-2025 | $858.43M ▲ | $5.8B ▲ | $3.33B ▲ | $2.47B ▲ |
| Q1-2025 | $786.17M ▼ | $5.71B ▼ | $3.31B ▼ | $2.4B ▼ |
| Q4-2024 | $1.04B ▲ | $5.93B ▼ | $3.53B ▼ | $2.4B ▼ |
| Q3-2024 | $1.02B | $6.75B | $3.54B | $3.21B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19.59M ▼ | $219.92M ▲ | $-86.45M ▼ | $-1.53M ▲ | $131.94M ▼ | $190.03M ▲ |
| Q2-2025 | $-1.19M ▲ | $89.02M ▲ | $224.9M ▲ | $-4.51M ▲ | $309.97M ▲ | $46.67M ▲ |
| Q1-2025 | $-101.22M ▲ | $30.81M ▼ | $-34.44M ▲ | $-256.17M ▼ | $-259.51M ▼ | $-365K ▼ |
| Q4-2024 | $-864.59M ▼ | $47.06M ▼ | $-41.87M ▲ | $10.5M ▲ | $11.97M ▼ | $10.75M ▼ |
| Q3-2024 | $-38.24M | $138.72M | $-81.72M | $-226K | $58.65M | $112.56M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Precision Oncology | $160.00M ▲ | $160.00M ▲ | $180.00M ▲ | $180.00M ▲ |
 Screening | $540.00M ▲ | $550.00M ▲ | $630.00M ▲ | $670.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $50.00M ▲ | $50.00M ▲ | $60.00M ▲ | $60.00M ▲ |
 UNITED STATES | $670.00M ▲ | $660.00M ▼ | $760.00M ▲ | $790.00M ▲ |
CEO
Kevin T. Conroy
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 215
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
TD Cowen
Buy
Craig-Hallum
Buy
B of A Securities
Buy
Baird
Outperform
Evercore ISI Group
Outperform
Scotiabank
Sector Outperform
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
FMR LLC
Shares:18.65M
Value:$1.91B
VANGUARD GROUP INC
Shares:17.81M
Value:$1.82B
CAPITAL WORLD INVESTORS
Shares:16.14M
Value:$1.65B
Summary
Showing Top 3 of 744